
Happiness Biotech Group Limited HAPP
Geschäftsbericht 2022
hinzugefügt 16.08.2022
Happiness Biotech Group Limited Betriebszyklus 2011-2026 | HAPP
Betriebszyklus Jährlich Happiness Biotech Group Limited
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 133 | 178 | 195 | 103 | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 195 | 103 | 152 |
Betriebszyklus anderer Aktien in der Pharmaeinzelhändler
| Name | Betriebszyklus | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
AstraZeneca PLC
AZN
|
206 | - | - | $ 96.9 B | ||
|
Celldex Therapeutics
CLDX
|
321 | $ 34.55 | 2.04 % | $ 2.29 B | ||
|
I-Mab
IMAB
|
271 | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | ||
|
Alnylam Pharmaceuticals
ALNY
|
102 | $ 309.66 | -3.27 % | $ 40.6 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
32 | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
245 | - | -18.52 % | $ 27.3 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
237 | $ 22.88 | 4.91 % | $ 1.07 B | ||
|
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | ||
|
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - | ||
|
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | ||
|
Aeterna Zentaris
AEZS
|
115 | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | ||
|
BioXcel Therapeutics
BTAI
|
1.66 K | $ 1.15 | 7.48 % | $ 14 M | ||
|
Akebia Therapeutics
AKBA
|
210 | $ 1.41 | 4.07 % | $ 363 M | ||
|
Ayala Pharmaceuticals
AYLA
|
61.7 | - | - | $ 7.46 M | ||
|
Aquestive Therapeutics
AQST
|
223 | $ 4.32 | 1.41 % | $ 462 M | ||
|
Arcutis Biotherapeutics
ARQT
|
291 | $ 24.53 | 1.41 % | $ 3.12 B | ||
|
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | ||
|
BioDelivery Sciences International
BDSI
|
436 | - | -4.8 % | $ 255 M | ||
|
Autolus Therapeutics plc
AUTL
|
129 | $ 1.6 | -0.62 % | $ 426 M | ||
|
BeiGene, Ltd.
BGNE
|
52.6 | - | 0.49 % | $ 251 B | ||
|
bluebird bio
BLUE
|
127 | - | - | $ 546 M | ||
|
Cidara Therapeutics
CDTX
|
2.26 K | - | - | $ 1.41 B |